Biocept, Inc. to Present at the American Association for Cancer Research Annual Meeting on Ability of its CEE-SelectorTM Technology to Enhance the Sensitivity of Sequencing for Rare Mutation Detection

Published: Apr 05, 2013

Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer, is presenting a poster at the 103rd Annual Meeting of the American Association for Cancer Research, being held in Washington DC April 6 – April 10, on improvements to the company’s ultra-sensitive mutation detection technology, CEE-SelectorTM, that significantly increase the sensitivity of standard or next generation sequencing.

Back to news